MedTrace Logo

Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse

NCT06738537 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-12-17

No results posted yet for this study

Summary

This is a qualitative and quantitative study that seeks to obtain information from patients with degenerative mitral valve prolapse and providers regarding factors important in deciding between surgical mitral valve repair (MVR) and transcatheter edge-to-edge repair (TEER). Findings from this study will provide data that can be used to develop decision aids that can assist patients in decision making between these two therapies and assist providers in integrating shared decision making the within the multidisciplinary heart valve team.

Conditions

  • Mitral Valve Prolapse

Interventions

OTHER

Focus Groups/Quantitative Survey for Patients

5 quantitative focus groups will be conducted with 5-10 patients each to elicit the range of outcomes patients consider important when selecting treatment options. 100 quantitative surveys to characterize how patients with severe MR prioritize outcomes when making treatment decisions.

OTHER

Focus Group/Quantitative Survey for HCPs

5 quantitative focus groups will be conducted with 5-10 providers to elicit the range of outcomes providers consider important when recommending treatment options to patients. 100 quantitative surveys to characterize how providers prioritize outcomes for patients with severe MR when making treatment recommendations.

OTHER

Qualitative Focus Group

Qualitative focus groups will be conducted to determine barriers and facilitators to implementing shared decision making in multidisciplinary mitral valve heart team clinics.

Sponsors & Collaborators

  • West Virginia University

    collaborator OTHER

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • The Cleveland Clinic

    collaborator OTHER

  • University of Kansas Medical Center

    collaborator OTHER

  • Saint Luke's Mid America Heart Institute

    collaborator UNKNOWN

  • Northwell Health

    lead OTHER

Principal Investigators

  • Alexander Iribarne, MD, MS, FACC · Northwell Health

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-01-28
Completion
2025-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738537 on ClinicalTrials.gov